Corcept Therapeutics (CORT)

AI Score

Unlock

69.63

2.20 (3.26%)

At close: Apr 15, 2025, 3:59 PM

70.71

1.56%

After-hours: Apr 15, 2025, 07:36 PM EDT

Dividends

No dividend history available for Corcept Therapeutics.

Pro Subscription

Upgrade now for unlimited access to all data and tools.

Dividend Definition

Dividends are payments made by a company to its shareholders, typically derived from its profits. They represent a portion of earnings distributed to investors as a reward for holding shares. Dividends do not account for retained earnings or reinvestments and are therefore different from a company's total profits.

Related Stocks

Company	Dividend Yield

Dividend Rankings

CORT News

22 hours ago · It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder - seekingalpha.com
5 days ago · 3 Biopharmaceutical Stocks Bucking the Sell-Off - marketbeat.com
1 week ago · Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer - businesswire.com
2 weeks ago · Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect? - zacks.com
2 weeks ago · Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release - seekingalpha.com
2 weeks ago · CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal - zacks.com
2 weeks ago · Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar? - zacks.com
2 weeks ago · Here's Why Momentum in Corcept (CORT) Should Keep going - zacks.com
2 weeks ago · Corcept Therapeutics: The ROSELLA Trial Presents A Major Win For The Company - seekingalpha.com
2 weeks ago · Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast - benzinga.com